Biochemical failure after carbon ion radiotherapy for prostate cancer

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3267-3274

  Shimazaki, Jun ^a,b   Tsuji, Hiroshi ^a   Ishikawa, Hitoshi ^a   Kamada, Tadashi ^a   Harada, Masaoki ^c   Akakura, Koichiro ^b   Suzuki, Hiroyoshi ^b   Ichikawa, Tomohiko ^b   Tsujii, Hirohiko ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

Author keywords

Biochemical failure; Carbon ion radiotherapy; External beam radiation therapy; Prostate cancer; Risk factor

Indexed keywords

BICALUTAMIDE; GONADORELIN AGONIST;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; ION THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SALVAGE THERAPY; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARBON RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 84865684360     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Vital Statistics Japan. Ministry of Health, Labor and Welfare, Tokyo, Japan.
2. Tsuji H, Yanagi T, Ishikawa H, Kamada T, Mizoe J-E, Kanai T, Morita S, Tsujii H and Working Group for Genitourinary Tumors: Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phy 63: 1153-1160, 2005.
3. Ishikawa H, Tsuji H, Kamada T, Yanagi T, Mizoe J-E, Kanai T, Morita S, Wakatsuki M, Shimazaki J, Tsujii H and Working Group for Genitourinary Tumors: Carbon ion radiation therapy for prostate cancer: Results of a prospective phase II study. Radiother Oncol 81: 57-64, 2006.
4. Shimazaki J, Tsuji H, Ishikawa H, Okada T, Akakura K, Suzuki H, Harada M and Tsujii H: Carbon ion radiotherapy for treatment of prostate cancer and subsequent outcomes after biochemical failure. Anticancer Res 30: 5105-5112, 2010
5. TNM Classification of Malignant Tumours. Seventh edition Sobin LH, Gospodarowicz MK, Wittekind Ch (eds.). UICC, Geneva, Switzerland, p. 230, 2009.
6. Epstein JI, Allsbrook WC, Amin MB, Egevad LL and ISUP Grading committee: The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29: 1228-1242, 2005.
7. Mostofi FK, Sesterhennb I and Sobin LH: Histological typing of prostate tumors. In: International Histological Classification of Tumors No. 22.WHO, Geneva, p. 18, 1980.
8. NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer, V 1, National Comprehensive Cancer Network, Fort Washington, PA, 19034, USA, 2011.
9. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP and Zattoni F: EAU Guidelines on prostate cancer. Eur Urol 53: 68-80, 2008.
10. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S and Pollack A: Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 79: 1310-1317, 2011.
11. Peeters STH, Heemsbergen WD, Koper PCM, van Putten WLJ, Slot A, Dielwart MFH, Bonfrer JMG, Incrocci L, and Lebesque JV: Dose response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24: 1990-1996, 2006.
12. Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, Cox B, Yamada Y, Fidaleo A, Sperling D, Happersett L and Zhang Z: Dose escalation for prostate cancer radiotherapy: Predictors of long-term biochemical tumor control and distant metastasis-free survival outcomes. Eur Urol 60: 1133-1139, 2011.
13. Valdagni R, Nahum AE, Magnani T, Italia C, Lanceni A, Montanaro P, Rancati T, Avuzzi B and Fiorino C: Long-term biochemical control of prostate cancer after standard or hyperfractionation: Evidence for different outcomes between low-intermediate and high risk patients. Radiother Oncol 101: 454-459, 2011.
14. Yeoh EE, Botten RJ, Butters J, DiMatteo AC, Holloway RH and Fowler J: Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 81: 1271-1278, 2011.
15. Kupelian PA, Willoughby TR, Reddy CA, Klein EA and Mahadevan A: Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68: 1424-1430, 2007.
16. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR and Rossi CJ: Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 28: 1106-1111, 2010.
17. Taira AV, Merrick GS, Galbreath RW. Wallner KE, and Butler WM: Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 76: 349-354, 2010.
18. Stone NN, Stock RG, Cesaretti JA and Unger P: Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 76: 355-360, 2010.
19. Al-Mamgani A, Heemsbergen WD, Levendag PC, and Lebesgue JV: Subgroup analysis of patients with localized prostate cancer treated within the Dutch randomized dose escalation trial. Radiother Oncol 96: 13-18, 2010.
20. Faria S, Dal Pra A, Cury F, David M, Duclos M, Freeman CR and Souhami L: Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone, Radiother Oncol 101: 486-489, 2011.
21. D'Amico AV, Whittington R, Malkowicz SB, Schulz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ and Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974, 1998.
22. Viani GA, Stefano EJ and Afonso SL: Higher-than-conventional radiation doses in localized prostate cancer treatment: a metaanalysis of randomized, controlled trials. Int. J Radiat Oncol Biol Phys 74: 1405-1418, 2009.
23. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, Marzi S, Landoni V, Fowler J and Strigari L: A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78: 11-18, 2010.
24. Morikawa LK and Roach III M: Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys 80: 6-16, 2011.
25. Pinkawa M, Piroth MD, Holy R, Fischedick K, Klotz J, Szekely- Orban D and Eble MJ: Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: A matched-pair comparison. Int J Radiat Oncol Biol Phy 81: 23-28, 2011.
26. Cuppone, F, Bria E, Giannarelli D, Vaccaro V, Milella M, Nistico C, Ruggeri EM, Sperduti I, Bracarda S, Pinnaro P, Lanzetta G, Muti P, Cognetti F and Carlini P: Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials. BMC Cancer 10: 675, 2010.
27. Bolla M: Current status of combined radiation therapy and androgen suppression in locally advanced prostate cancer: What is the way forward ? Eur Urol Suppl 9: 788-793, 2010.
28. Parikh R and Sher DJ: Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: A decision analysis. Cancer 118: 258-267, 2012.
29. Chan TY, Partin AW, Walsh PC and Epstein JI: Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 56: 823-827, 2000.
30. D'Ambrosio DJ, Hanlon AL, Al-Saleem T, Feigenberg SJ, Horwitz EM, Uzzo RG, Pollack A, and Buyyounouski MK: The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 67: 1082-1087, 2007.
31. Nanda A, Chen M-H, Renshaw AA and D'Amico AV: Gleason pattern 5 prostate cancer: Further stratification of patients with high-risk disease and implications for further randomized trials. Int J Radiat Oncol Biol Phys 74: 1419-1423, 2009.
32. Sabolch A, Feng FY, Daignault-Newton S, Halverson S, Blas K, Phelps L, Olson KB, Sandler HM and Hamstra DA: Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 81: e351-360, 2011.
33. Buyyounouski MK, Hanlon AL, Horwitz EM and Pollack A: Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy, Int J Radiat Oncol Biol Phys 70: 59-66, 2007.
34. Tomioka S, Shimbo M, Amiya Y, Nakatsu H, Murakami S and Shimazaki J: Outcome of patients with hormone-refractory prostate cancer: Prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen. Jpn J Clin Oncol 38: 36-42, 2008.